Loading…
Design, synthesis and biological evaluation of novel nitric oxide-donating protoberberine derivatives as antitumor agents
A novel class of NO-donating protoberberine derivatives were synthesized and initially evaluated for their anti-hepatocellular carcinoma activities. Most of the compounds exhibited more potent activity against HepG2 cells than parent compounds berberine and palmatine. In particular, compound 15a exe...
Saved in:
Published in: | European journal of medicinal chemistry 2017-05, Vol.132, p.173-183 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c362t-7726d65da4720c77ee6d4646e2b6afa962274929f3e12c264f4da618ac0639aa3 |
---|---|
cites | cdi_FETCH-LOGICAL-c362t-7726d65da4720c77ee6d4646e2b6afa962274929f3e12c264f4da618ac0639aa3 |
container_end_page | 183 |
container_issue | |
container_start_page | 173 |
container_title | European journal of medicinal chemistry |
container_volume | 132 |
creator | Chen, Jichao Wang, Tianyu Xu, Shengtao Lin, Aijun Yao, Hequan Xie, Weijia Zhu, Zheying Xu, Jinyi |
description | A novel class of NO-donating protoberberine derivatives were synthesized and initially evaluated for their anti-hepatocellular carcinoma activities. Most of the compounds exhibited more potent activity against HepG2 cells than parent compounds berberine and palmatine. In particular, compound 15a exerted the strongest activity with an IC50 value of 1.36 μM. Moreover, most compounds released moderate levels of NO in vitro, and the antitumor activity of 15a in HepG2 cells was remarkably diminished by an NO scavenger. Interestingly, compound 15a displayed a broad-spectrum antitumor efficacy and possessed good selectivity between tumor cells (HepG2, SMMC-7721, HCT-116, HL-60) and normal liver LO-2 cells. The mechanism studies revealed that 15a blocked the G2 phase of the cell cycle and induced apoptosis of HepG2 cells by mitochondrial depolarization. Furthermore, 15a inhibited tumor growth in H22 liver cancer xenograft mouse model by 62.5% (w/w), which was significantly superior to parent compound palmatine (41.6%, w/w). Overall, the current study may provide a new approach for the discovery of novel antitumor agents.
[Display omitted]
•Eighteen novel NO-donating protoberberine derivatives were synthesized.•Most compounds showed significantly enhanced in vitro anti-proliferative activity.•15a exhibited good selectivity between tumor cells and normal liver LO-2 cells.•The antitumor activity of 15a in HepG2 cells was diminished by an NO scavenger.•15a effectively inhibited liver tumor growth in an in vivo mouse model. |
doi_str_mv | 10.1016/j.ejmech.2017.03.027 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1883177323</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0223523417301848</els_id><sourcerecordid>1883177323</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-7726d65da4720c77ee6d4646e2b6afa962274929f3e12c264f4da618ac0639aa3</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVpSLZp_kEpOvZQu_qyZF8KJU3aQiCX9Cy00nijxZZSSTbZfx8tm_ZYGJiBeeedmQehD5S0lFD5Zd_Cfgb72DJCVUt4S5h6gzZUyb7hrBNv0YYwxpuOcXGB3uW8J4R0kpBzdMF63g1EdBt0-A7Z78JnnA-hPNY6YxMc3vo4xZ23ZsKwmmkxxceA44hDXGHCwZfkLY7P3kHjYqjtsMNPKZa4hVTDB8CuprV2VqieR9viyzLHhM0OQsnv0dlopgxXr_kS_b69ebj-2dzd__h1_e2usVyy0ijFpJOdM0IxYpUCkE5IIYFtpRnNIBlTYmDDyIEyy6QYhTOS9sYSyQdj-CX6dPKt5_1ZIBc9-2xhmkyAuGRN-55TpTjjVSpOUptizglG_ZT8bNJBU6KP0PVen6DrI3RNuK7Q69jH1w3Ldgb3b-gv5Sr4ehJA_XP1kHS2HoIF5xPYol30_9_wAuUulz0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1883177323</pqid></control><display><type>article</type><title>Design, synthesis and biological evaluation of novel nitric oxide-donating protoberberine derivatives as antitumor agents</title><source>Elsevier</source><creator>Chen, Jichao ; Wang, Tianyu ; Xu, Shengtao ; Lin, Aijun ; Yao, Hequan ; Xie, Weijia ; Zhu, Zheying ; Xu, Jinyi</creator><creatorcontrib>Chen, Jichao ; Wang, Tianyu ; Xu, Shengtao ; Lin, Aijun ; Yao, Hequan ; Xie, Weijia ; Zhu, Zheying ; Xu, Jinyi</creatorcontrib><description>A novel class of NO-donating protoberberine derivatives were synthesized and initially evaluated for their anti-hepatocellular carcinoma activities. Most of the compounds exhibited more potent activity against HepG2 cells than parent compounds berberine and palmatine. In particular, compound 15a exerted the strongest activity with an IC50 value of 1.36 μM. Moreover, most compounds released moderate levels of NO in vitro, and the antitumor activity of 15a in HepG2 cells was remarkably diminished by an NO scavenger. Interestingly, compound 15a displayed a broad-spectrum antitumor efficacy and possessed good selectivity between tumor cells (HepG2, SMMC-7721, HCT-116, HL-60) and normal liver LO-2 cells. The mechanism studies revealed that 15a blocked the G2 phase of the cell cycle and induced apoptosis of HepG2 cells by mitochondrial depolarization. Furthermore, 15a inhibited tumor growth in H22 liver cancer xenograft mouse model by 62.5% (w/w), which was significantly superior to parent compound palmatine (41.6%, w/w). Overall, the current study may provide a new approach for the discovery of novel antitumor agents.
[Display omitted]
•Eighteen novel NO-donating protoberberine derivatives were synthesized.•Most compounds showed significantly enhanced in vitro anti-proliferative activity.•15a exhibited good selectivity between tumor cells and normal liver LO-2 cells.•The antitumor activity of 15a in HepG2 cells was diminished by an NO scavenger.•15a effectively inhibited liver tumor growth in an in vivo mouse model.</description><identifier>ISSN: 0223-5234</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2017.03.027</identifier><identifier>PMID: 28359045</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Animals ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacology ; Antitumor activity ; Apoptosis - drug effects ; Berberine ; Berberine Alkaloids - chemistry ; Berberine Alkaloids - pharmacology ; Carcinoma, Hepatocellular - drug therapy ; Cell Cycle Checkpoints - drug effects ; Hep G2 Cells ; Heterografts ; Humans ; Hybrid compound ; Liver Neoplasms - drug therapy ; Mice ; Nitric oxide (NO) donor ; Nitric Oxide - metabolism ; Palmatine</subject><ispartof>European journal of medicinal chemistry, 2017-05, Vol.132, p.173-183</ispartof><rights>2017 Elsevier Masson SAS</rights><rights>Copyright © 2017 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-7726d65da4720c77ee6d4646e2b6afa962274929f3e12c264f4da618ac0639aa3</citedby><cites>FETCH-LOGICAL-c362t-7726d65da4720c77ee6d4646e2b6afa962274929f3e12c264f4da618ac0639aa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28359045$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Jichao</creatorcontrib><creatorcontrib>Wang, Tianyu</creatorcontrib><creatorcontrib>Xu, Shengtao</creatorcontrib><creatorcontrib>Lin, Aijun</creatorcontrib><creatorcontrib>Yao, Hequan</creatorcontrib><creatorcontrib>Xie, Weijia</creatorcontrib><creatorcontrib>Zhu, Zheying</creatorcontrib><creatorcontrib>Xu, Jinyi</creatorcontrib><title>Design, synthesis and biological evaluation of novel nitric oxide-donating protoberberine derivatives as antitumor agents</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>A novel class of NO-donating protoberberine derivatives were synthesized and initially evaluated for their anti-hepatocellular carcinoma activities. Most of the compounds exhibited more potent activity against HepG2 cells than parent compounds berberine and palmatine. In particular, compound 15a exerted the strongest activity with an IC50 value of 1.36 μM. Moreover, most compounds released moderate levels of NO in vitro, and the antitumor activity of 15a in HepG2 cells was remarkably diminished by an NO scavenger. Interestingly, compound 15a displayed a broad-spectrum antitumor efficacy and possessed good selectivity between tumor cells (HepG2, SMMC-7721, HCT-116, HL-60) and normal liver LO-2 cells. The mechanism studies revealed that 15a blocked the G2 phase of the cell cycle and induced apoptosis of HepG2 cells by mitochondrial depolarization. Furthermore, 15a inhibited tumor growth in H22 liver cancer xenograft mouse model by 62.5% (w/w), which was significantly superior to parent compound palmatine (41.6%, w/w). Overall, the current study may provide a new approach for the discovery of novel antitumor agents.
[Display omitted]
•Eighteen novel NO-donating protoberberine derivatives were synthesized.•Most compounds showed significantly enhanced in vitro anti-proliferative activity.•15a exhibited good selectivity between tumor cells and normal liver LO-2 cells.•The antitumor activity of 15a in HepG2 cells was diminished by an NO scavenger.•15a effectively inhibited liver tumor growth in an in vivo mouse model.</description><subject>Animals</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antitumor activity</subject><subject>Apoptosis - drug effects</subject><subject>Berberine</subject><subject>Berberine Alkaloids - chemistry</subject><subject>Berberine Alkaloids - pharmacology</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Cell Cycle Checkpoints - drug effects</subject><subject>Hep G2 Cells</subject><subject>Heterografts</subject><subject>Humans</subject><subject>Hybrid compound</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Mice</subject><subject>Nitric oxide (NO) donor</subject><subject>Nitric Oxide - metabolism</subject><subject>Palmatine</subject><issn>0223-5234</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kE1r3DAQhkVpSLZp_kEpOvZQu_qyZF8KJU3aQiCX9Cy00nijxZZSSTbZfx8tm_ZYGJiBeeedmQehD5S0lFD5Zd_Cfgb72DJCVUt4S5h6gzZUyb7hrBNv0YYwxpuOcXGB3uW8J4R0kpBzdMF63g1EdBt0-A7Z78JnnA-hPNY6YxMc3vo4xZ23ZsKwmmkxxceA44hDXGHCwZfkLY7P3kHjYqjtsMNPKZa4hVTDB8CuprV2VqieR9viyzLHhM0OQsnv0dlopgxXr_kS_b69ebj-2dzd__h1_e2usVyy0ijFpJOdM0IxYpUCkE5IIYFtpRnNIBlTYmDDyIEyy6QYhTOS9sYSyQdj-CX6dPKt5_1ZIBc9-2xhmkyAuGRN-55TpTjjVSpOUptizglG_ZT8bNJBU6KP0PVen6DrI3RNuK7Q69jH1w3Ldgb3b-gv5Sr4ehJA_XP1kHS2HoIF5xPYol30_9_wAuUulz0</recordid><startdate>20170526</startdate><enddate>20170526</enddate><creator>Chen, Jichao</creator><creator>Wang, Tianyu</creator><creator>Xu, Shengtao</creator><creator>Lin, Aijun</creator><creator>Yao, Hequan</creator><creator>Xie, Weijia</creator><creator>Zhu, Zheying</creator><creator>Xu, Jinyi</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170526</creationdate><title>Design, synthesis and biological evaluation of novel nitric oxide-donating protoberberine derivatives as antitumor agents</title><author>Chen, Jichao ; Wang, Tianyu ; Xu, Shengtao ; Lin, Aijun ; Yao, Hequan ; Xie, Weijia ; Zhu, Zheying ; Xu, Jinyi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-7726d65da4720c77ee6d4646e2b6afa962274929f3e12c264f4da618ac0639aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antitumor activity</topic><topic>Apoptosis - drug effects</topic><topic>Berberine</topic><topic>Berberine Alkaloids - chemistry</topic><topic>Berberine Alkaloids - pharmacology</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Cell Cycle Checkpoints - drug effects</topic><topic>Hep G2 Cells</topic><topic>Heterografts</topic><topic>Humans</topic><topic>Hybrid compound</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Mice</topic><topic>Nitric oxide (NO) donor</topic><topic>Nitric Oxide - metabolism</topic><topic>Palmatine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Jichao</creatorcontrib><creatorcontrib>Wang, Tianyu</creatorcontrib><creatorcontrib>Xu, Shengtao</creatorcontrib><creatorcontrib>Lin, Aijun</creatorcontrib><creatorcontrib>Yao, Hequan</creatorcontrib><creatorcontrib>Xie, Weijia</creatorcontrib><creatorcontrib>Zhu, Zheying</creatorcontrib><creatorcontrib>Xu, Jinyi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Jichao</au><au>Wang, Tianyu</au><au>Xu, Shengtao</au><au>Lin, Aijun</au><au>Yao, Hequan</au><au>Xie, Weijia</au><au>Zhu, Zheying</au><au>Xu, Jinyi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Design, synthesis and biological evaluation of novel nitric oxide-donating protoberberine derivatives as antitumor agents</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2017-05-26</date><risdate>2017</risdate><volume>132</volume><spage>173</spage><epage>183</epage><pages>173-183</pages><issn>0223-5234</issn><eissn>1768-3254</eissn><abstract>A novel class of NO-donating protoberberine derivatives were synthesized and initially evaluated for their anti-hepatocellular carcinoma activities. Most of the compounds exhibited more potent activity against HepG2 cells than parent compounds berberine and palmatine. In particular, compound 15a exerted the strongest activity with an IC50 value of 1.36 μM. Moreover, most compounds released moderate levels of NO in vitro, and the antitumor activity of 15a in HepG2 cells was remarkably diminished by an NO scavenger. Interestingly, compound 15a displayed a broad-spectrum antitumor efficacy and possessed good selectivity between tumor cells (HepG2, SMMC-7721, HCT-116, HL-60) and normal liver LO-2 cells. The mechanism studies revealed that 15a blocked the G2 phase of the cell cycle and induced apoptosis of HepG2 cells by mitochondrial depolarization. Furthermore, 15a inhibited tumor growth in H22 liver cancer xenograft mouse model by 62.5% (w/w), which was significantly superior to parent compound palmatine (41.6%, w/w). Overall, the current study may provide a new approach for the discovery of novel antitumor agents.
[Display omitted]
•Eighteen novel NO-donating protoberberine derivatives were synthesized.•Most compounds showed significantly enhanced in vitro anti-proliferative activity.•15a exhibited good selectivity between tumor cells and normal liver LO-2 cells.•The antitumor activity of 15a in HepG2 cells was diminished by an NO scavenger.•15a effectively inhibited liver tumor growth in an in vivo mouse model.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>28359045</pmid><doi>10.1016/j.ejmech.2017.03.027</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0223-5234 |
ispartof | European journal of medicinal chemistry, 2017-05, Vol.132, p.173-183 |
issn | 0223-5234 1768-3254 |
language | eng |
recordid | cdi_proquest_miscellaneous_1883177323 |
source | Elsevier |
subjects | Animals Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Antitumor activity Apoptosis - drug effects Berberine Berberine Alkaloids - chemistry Berberine Alkaloids - pharmacology Carcinoma, Hepatocellular - drug therapy Cell Cycle Checkpoints - drug effects Hep G2 Cells Heterografts Humans Hybrid compound Liver Neoplasms - drug therapy Mice Nitric oxide (NO) donor Nitric Oxide - metabolism Palmatine |
title | Design, synthesis and biological evaluation of novel nitric oxide-donating protoberberine derivatives as antitumor agents |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T05%3A36%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Design,%20synthesis%20and%20biological%20evaluation%20of%20novel%20nitric%20oxide-donating%20protoberberine%20derivatives%20as%20antitumor%20agents&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=Chen,%20Jichao&rft.date=2017-05-26&rft.volume=132&rft.spage=173&rft.epage=183&rft.pages=173-183&rft.issn=0223-5234&rft.eissn=1768-3254&rft_id=info:doi/10.1016/j.ejmech.2017.03.027&rft_dat=%3Cproquest_cross%3E1883177323%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c362t-7726d65da4720c77ee6d4646e2b6afa962274929f3e12c264f4da618ac0639aa3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1883177323&rft_id=info:pmid/28359045&rfr_iscdi=true |